ALT - Earnings call transcript Q2 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to Altimmune, Inc.

Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to introduce your host for today's conference call, Lee Roth of Burns McClellan, Investor Relations Advisors to Altimmune.

Lee Roth

Thanks, Gigi. everyone. morning, Good participating Results for Altimmune Quarter Second Thank Business on Update Financial and Conference XXXX you the Call. Medical Scott Members of Garg, our Chief Officer; Vipin and Andrew Financial Shutterly, Roberts, today me Jordt, our Chief Business Harris, acting Officer; the Altimmune our our team Chief Chief joining Officer. Officer; our Ray Officer; Chief are Scot Executive Scientific

session. Scott Following and Andrew, Q&A from a Vipin, Harris remarks prepared hold weâ€™ll

this morning As company's our issued financial release results the our on with website. the XXXX can a QX and IR reminder, press of found be was section

everyone Before cause prospects remarks indicated. forward-looking statements we materially Altimmune our begin, purposes provisions I'd could like to statements Litigation subject differ from forward-looking those are Private future to of and XXXX. and remind Reform plans the that safe uncertainties of that harbor that actual under cautions expectations, these for risks to the about results constitute Securities Act

not factors today. to our of forward-looking the on occur any For impact statement risk issued today's some these speak does or made to only SEC. and forward-looking obligation after earlier contained a other future date, discussion XXXX, of website. factors refer as to events any statements Thursday, available today undertake our you the in and in during release circumstances now company or of and on the of statements update Any this press call and the reflect direct with read August cautionary to that that and X, please I'll the filings company's disclaimer the statements could results operations, our the also risks

Garg, now will that, Executive is for Officer Altimmune. call available the replay pleasure Dr. call turn of this reminder, the it's to Altimmune Vipin audio to be over website. a recorded Chief on being and With my As

Vipin Garg

half of again, and variety Lee. with differentiated update. the rationale therapeutic corporate pemvidutide in the highly us first for to significant continued second throughout In our quarter the of and we morning, everyone, joining potential you strengthen Thanks, diseases. second the Good for thank a metabolic once for quarter as year, a

data from to in programs. clinical and excited approaching important obesity key continuing operational and both are for of are priorities quarter are our MOMENTUM that milestones lean the advance meeting class-leading was EASL June, presented body scientific highlighted on ADA The composition prominent Phase the pemvidutide that the MASH We that the At sessions in The our by obesity we strategic loss. The our weight the at X Diabetes effects among presentations X increasing preservation lean most of meetings preservation Congress. of Association medical data Study trial our loss mass important of updated safety of quality European on for the a ADA's or is the Liver in and the or treatment XX and the of the space. Association long-term becoming of maintenance of mass obesity and demonstrated American increasingly for and agents. weight for

and the fibrosis pemvidutide, remain reinforces of resolution in structures. In Congress confidence achieving a discussions engaged disease-modifying a pemvidutide MASH MASH our ease our of the presented highlighted in addition, and regarding Xb of potential we strategic in possible in variety during transaction the We trial. Phase both for global IMPACT that data endpoint involving

especially to us right create identifying value which indications focused full completing on metabolic vision, well and to and we intently for additional In intend by conditions. the pursuing obesity, MASH are potential of a the and IMPACT realize study securing and other the pemvidutide parallel, help additional We commitment partner suited. in pemvidutide resources with

differentiated the meeting the The to confirm for believe, patient outcome program of meeting for our Phase obesity. of end of Dr. the with additional call Scott prepare this FDA from and X to I'll most to Harris will over discuss registrational Medical the Chief With provide will Officer, updates turn plans. pemvidutide. review population, that, to benefit now continue our the we we Finally, profile our

M. Harris

of XX% significant as the XX.X% a weeks, to in nearly in at To the data and associated to turn XX.X% subset affects direct Aronne, a some dyslipidemia, treatment dose. showed mass pemvidutide dyslipidemia of pemvidutide cholesterol much of meetings. points bit Vipin. the of with Aronne also many meeting, associated higher at presented I'd as has been that believe trial, Dr. the total of weight account treatment. with led trajectory a attributed presented Available lean in was weight recent obesity Dr. mortality. fat in lean class-leading more loss. in lean a as obesity total like pemvidutide of discussed, XX% of obesity data Thank loss as cardiovascular demonstrated of with investigator among bone metabolic function our showing information loss patients, obesity X.X important loss mass shown reduction led In in and lean you XX.X% management XX data at milligram foremost incretin-based with of of becoming the MOMENTUM At continued subjects cholesterol ADA provide reduced suggesting Since of in to lean effects for data incretin weight you, LDL of on weight consideration as The one scientific at serum with that lipids XX% other associated additional agents reduction loss weight mass, loss while is physical Louis XX% loss. benefit rates the to that preservation triglycerides, preservation that agents fractures, increasingly pronounced the body presented disease the that pemvidutide reduction can population. presented at analysis to only we experts with an loss and ADA also risk. obesity The mass composition segment with loss of has mass a updated have weight and XX.X% could principal

weight robust agents. higher-quality preservation We well space lipids to weight safe is loss the evolving in maintenance believe obesity robust comorbidities fat and mass the were its monotherapy benefits with the clinically cardiovascular ability reductions with on achieve excellent that in of of loss observed recent the of liver observed with lipids effective serum trial, in with cardiovascular and degrees meaningful. address and fat towards not narrative we The and pemvidutide, directly obesity. pemvidutide serum effects with other positioned the loss, and in benefit that associated weight liver lipids GLP with were greater SELECT compared liver this is its can even of reductions significant population. While the and We believe

to a designed of share from on the our comprehensive will end FDA for X We and data of of We with unique our these look differentiation FDA X package approach forward obesity. as meeting. upcoming driven program to Phase the feedback part a Phase

this an outcome the when with of FDA update provide dialogue will on the We complete. meeting is the

Turning that high to of a IMPACT predict quantitative the likelihood success the a from model upcoming MASH. We presented EASL data trial. in would at Congress

subjects improvement with receiving MASH rates resolution In FAST that aminotransferase IMPACT of addition, or as be X an MASLD, compared fibrosis Phase suggests Phase achieved FibroScan-aspartate alanine mass liver may aminotransferase analysis and trial. placebo. the that receiving and also score, MRI-PDFF This in of of proportions significant steatotic in data Xb in demonstrated disease, achieved improvements pemvidutide subjects metabolic-associated trial higher our known of

lower pemvidutide dyslipidemia ability that patients. mortality associated reminds of species data in We which cause in of the also the cardiovascular presented of MASH, lipid on us the serum benefits primary match with

differentiated this the in incretin endpoints for in trial. as highlighted progressing With improvement of results for rapid enrollment impact, MASH published addition, MASLD time efficacy mass discontinuations fibrosis MASH. the the we therapeutic would recently results Journal low pemvidutide of tolerability transformative an rate space of effects be the a XX-week the in and resolution disease time trial we the was establishing in frame. and from X.X% and the our to the improvement treatment in MASLD, The are Hepatology, the XX-week first If respect adverse could XX-week pemvidutide by agent with believe in event safety pemvidutide of associated we demonstrate with liver achieved, In metabolic is well. our profile of of

pemvidutide year. With for Financial indications X details we now before, Officer, areas for financial turn I'll in our over need, pemvidutide, evaluate to value that, that believe, or benefits leverage allow will have We that our our review additional the that, to the create additional Andrew strategic Chief be to expect on this attractive medical of the us and as envision call to Shutterly, Finally, greatest quarter. provide we unmet to for discussed continuing up are indications develop we results to will and second acting later own. partners our additional more glucagon we to pursuing of

Andrew Shutterly

Thank again, you, morning and Scott, good everyone.

Quarter which available in trial update A second call, a million Form to be We Second I'll of providing be today. SEC more the XXXX will equivalents fully the IMPACT existing line project XXXX, readout our the in XXXX. compared short-term balance first that and QX cash, data. quarter Altimmune Results. today's XXXX Operating Financial top approximately biopsy brief funds For later Altimmune's of of investments cash at expected XXXX filed will including comprehensive million $XXX of and the be ended half MASH, $XXX.X information our on fund with with to the end XX-Q our into of us

the stock down of in $XX.X clinical HepTcell in were quarter with of statement. XXXX. increase of wind for during in of total $X.X due XX, primarily by awards, to the activities $XX.X in million of of $XX.X to we're March and on compared and closing to development in second direct government Revenue for development related Turning to XXXX was direct $X.X negligible million pemvidutide that period $X the as versus XXXX of The of XXXX second million including million expenses direct contract our was modification and XXXX. such million the R&D HepTcell associated now. the caused million direct quarter million in million and in million in the partially for of expense a conduct the programs, in XXXX second the XXXX. a expenses $X Any administrative expenses the indirect announced in were costs insurance activities. $X.X were expenses to $X.X pemvidutide increase Research reduction to second in related by related and $X.X period development expenses General same XXXX reported Approximately the development offset direct $XX.X compensation this costs expenses. quarter XXXX. of expenses the included for million quarter quarter in second of income second stock rate adjustments revenue and a quarter the in million on was closing

million, The million million $X.X back months was Our over increase of recurring XX, the loss $X.X quarterly share XXXX primarily trial for XXXX. million Vipin all noncash compared to operating for quarter execute MASH. for quarter for his net XXXX, the to the second a loss in ended the we per closing expenses or X net share IMPACT research increase net of loss Net in which second remarks. I'll attributable as $XX.X Phase now or quarter expenses $X.XX net June continue is to of per the $X.XX the development loss Xb it in $XX.X to were in and turn of expenses. loss was

Vipin Garg

Andrew. you, Thank

believe positioned We that open half for well ahead. and concludes like are the the are the and steps Operator, lie would optimistic opportunities to looking questions. With to take we that about that formal exciting remarks, XXXX. forward pemvidutide second of lines we year to early an upcoming multiple our we for are the milestones, and next

Operator

[Operator Instructions].

line the Yasmeen Sandler. Piper from of from comes question first Rahimi Our

Liam Hiester

Liam is for This on Hiester Yas.

a few questions. quick Just

if the rate MASH talk believe to resolution the about be that you first MASH So, competitive fibrosis one, could response the kindly in and you in space.

expectations are for then them? questions the considering milligram some for you any X.X-milligram with across would can Phase the discuss are to for And X population end meeting X.X the biopsy you great. the which provide your response going you dosing are on third, And of be endpoints. dose what X into patient key what with color if Secondly, to plan FDA, Phase

M. Harris

for thanks the questions, Well, Liam.

depends really So, the response it that you the see. response fibrosis resolution, placebo regarding rates for MASH and on

of, have higher And to response, you with a consequently, expect rate or if rate, improvement. resolution to XX% placebo response you'd MASH low So, much a a you're going fibrosis expect lower. say, placebo

that significance response about I that most delta really just is Even talk rates but setting. statistical to statistical endpoints. at we'll you And significance see So, achieved. start, in difficult both response thing on in the depends placebo actually important over as that is where mentioned. rates believe looking is only I The meaningful not

driven that the trial, you the dose dose dose endpoints question the X.X-milligram the saw we remind predominantly we we And second to liver MASH, the the in in that IMPACT reduction the that MASH the will response dose same in superior the the higher in X.X-milligram well. than that was trial. dose. fat as MASH your believe reduction be as response, endpoints in the substantially And in fat. dose, on pattern a Regarding in reduction same And by follow at milligram liver MOMENTUM trial the X.X the of will are think

because on FDA we composition we're marketplace. liver end pemvidutide in Lastly, questions intend Phase believe key regarding study bring this differentiated of differentiate and of the pemvidutide asking fat about that the to X we body out will the the which design, the that meeting, lipids, are our profile

of So, interaction out product the from to other attractive and program the a program, with our space. target will in compounds X Phase X FDA that we Phase are very the basically differentiating end be the in Phase commercially and X profile constructing bring

Operator

[Operator Instructions].

line the from Roger from comes Song of question next Our Jefferies.

Unknown Analyst

following on Phase potential endpoints is your up for Roger. X program. [indiscernible] for This Maybe on

at You ways or or at potential companies perhaps factor a match lipids, you then end are discussed are way are nuanced and what some collaboration can. detailed those And exploring? results other all those attractive into some body more than do fat, partnership could in point, you're liver, how structures partnerships, discussions? points you secondly, that measure on this And differentiate

M. Harris

about Coby ]. first I'll question and [ of collaborations. the X answer Thanks, trial, to Vipin endpoints take the second the the I'll about Phase ask question the

are endpoints changes. clear represent the that meaningful fairly clinical they think we because So,

a For with a clear fat and been very risk, of liver example, as serum strong the outcomes, lipids such cardiovascular are in other surrogate only but association a organs variety of there's for not cardiovascular outcomes kidney.

improvement very simply demonstrating So, of those be we endpoints will believe that meaningful.

think class-leading function physical end their also, As among incretin we mortality. but meaningful. in clinically has trials and mass have we some Many demonstrate, Vipin? approved also either extremely associated as points cases, these larger of mass would are that and important because that's loss mentioned, lean or the of stand of own on to fractures we in loss lean preservation surrogates they we been far believe take stand-alone as the And agents a of with development.

Vipin Garg

different can't So, full get get really the the to to The into with we details focus are regards the structure, of I value but specific the asset. structures, structures. open to for is multiple

in As you basically know, pemvidutide is pipeline a product.

We X indications got that are major pursuing. we have

indications. to want of capture sure to both we we upside are the make So, those able on

value So, to that many for there value able to so deal, are we and are so structure the capture different full get asset. the ways

Operator

[Operator Instructions].

question Sheoran next Our line from Seema comes of the from Evercore.

Seema Sheoran

Seema is Lisa. for This on

expect And pemvidutide. it my second data MASH you when is is expecting oral enrollment and in how be Phase first to on X you question you're can the As expand going on quarter, complete?

plan mentioned some are characteristics And Is of that to year-end. for? the case? that you the what announce a candidate you are You that looking by this of have still candidate

M. Harris

Seema. I'll oral Thanks, answer the Scot address I'll ask to candidates. first Roberts the question.

patients because represents So, than going weight well. that of is any extremely it that been other this and enrollment attractive the loss trial, enrolling is that mass trial that fact We've to faster the trial we're the offers. told

the the want a still about We date complete the trial question first the announcement will the to be screening Scot, been problem. results, estimated an address did can future, and which oral not on then XXXX. we the has the near believe screening in of in you quarter update of you So, formulation? provide intend to we do of

M. Roberts

question. Sure. Seema, thanks for the

efforts actually the still Our year. oral continuing. can development we're form We're we formulation the on of nominate that We've types formulations the looking of one end of formulations, are at the expanded these of number formulations. of for by hopeful prototype

with obviously small oral that formulations, Difficulty] the oral that an the I established as want I and [indiscernible] working. and is an important formulation oral success with we're the oral molecule [Technical of think equivalent peptide blood overall is same seeing are pemvidutide, that of the which to different pemvidutide formulation, the do loss really point peptide potency, event adverse formulation into Difficulty] an weight amount well But the that to concentrations delivers profile. at the profile what the the is [Technical there's

but loss levels So, you not we're really of adverse have really clearly to very active, and are know. the rates events, respect differentiated small weight molecules, that as with see also higher subcutaneous of peptides you which pushing with

goal project is oral with is pemvidutide think valuable. achieve clinical extremely like this formulation. So, to profile The the we still a

update you as we'll further there. we advances So, know

Operator

[Operator Instructions].

of next Goldman comes question Our Corinne Sachs. Jenkins from the from line

Omari Baruti

This is for Omari on Baruti Corinne.

the to remain executing So, approval. I done In how of to regulatory provided is Agency a partnership [indiscernible] approach an for seeking end Phase the steps about studies? prepare as your alignment questions. would wish as and you prior of then on And what next you by for wanted meeting have second, the list past, couple that And think partner? agency future you an have Does X aim?

Vipin Garg

question? your can you repeat sorry, I'm first

Omari Baruti

Sure.

agency partnership Does wanted against So, establish in next to to you inventory without executing had provided want improvement. that steps the aim? remain And think past, about a you would how to an a by prior partner? the

Vipin Garg

related indications. we MASH. the can that we have own our in a up So, in it's part flexibility X us on obesity of lined indications, in In partnership to additional before think partner been always We reason MASH, Phase goal And we these terms are at to has development prior story. gives looking the of different approval, a our take it in even look, forward start obesity. additional

of as Phase from to able evaluating. we'll what be we the planned information, as as the decision see get to And forward. make we end with we to have are other have the we move meeting discuss indications the X we'll well how better FDA to feedback interactions FDA additional that So, at that once a

M. Harris

the Omari, you you it. didn't going hear to quality this repeat ask I'm to good repeat because question? The question I Could is please the Scott. second wasn't audio enough.

Omari Baruti

is alignment sites? meeting approach for Phase and agency in the as to your for future prepare wishlist What you X

M. Harris

addressed this I previously. Well, was partially think

different repeatedly So, stressed patient is highly a going compound. differentiated obesity marketplace believe high fat. liver we We XX% segment we or believe is that of that We the marketplace needs. the dyslipidemic with have to that

than is loss. this also people this for treatment high be excessive the effects highlight might who the subject going that with lean consequently, the saying, liver and of of fat rather program muscle a So subjects a treatment We're serum obesity. for lipids, to high with program of is obesity, to

We're what of from Phase is approval it, approval for is So, differentiates saying we're obesity. our preceded and that discussion in others saying, this may focusing have X is not this that end going for that obesity, of an partners key but we the our compound. that will we think as on And product in the differentiation only marketplace attributes pemvidutide target will an for use which well. attractive potential be the to create not commercialize profile,

Operator

Instructions]. [Operator

comes Riley Mayank Securities. B. from Our next of line question Mamtani from the

William Wood

This is Mayank. on nice on the for Congratulations quarter. actually William

of from a Just couple questions us.

what Phase trials. Phase that land about Where Whether far? you've rate curious you've in seeing it you just so and IMPACT the NAFLD-earlier your in maybe are I'm expecting your diabetes, trial. first, variance to even X MOMENTUM been maybe The and X from be in trial seen discontinuation prior

M. Harris

you, William. Thank

which We pharmacokinetics itself either So, completion incretin in will we're drug the prove the development. agent, be of any the we any now contrast in of that XX without are stark dose that rates based up titrating compound to really best with or And tolerated the into remember titration, is the the believe believe weeks. of on pemvidutide, approved that studies with entry essentially agents seeing other slow to at bloodstream. to discontinuation

many Our observed, trials. weeks. dose adverse the discontinuation reduction, semaglutide were were without patients as for observed also, And of as allowing longest rates in X titration employed period event and those tirzepatide was which in XX% was that

and in of compound improving the and of tolerability Previously, not And publication going agency about subjects only in stack So, diabetes odd today again, the the the tremendous discontinuations we compound and we'll in our had for because And received the in with was with rate on feedback titration the of discontinuation have trial event dose Phase the the adverse discussions X, dose call that relative against absence as the X.X%. Hepatology, also adverse optionality reduction. event those Journal approach. of we who X their trial. of announced get have breast pemvidutide the allowing into and in we

we the forward, that going to of We One agency on feedback have titration period. Now lots get the can is options. the from extend proposal.

believe weight administered in clinical as Although produces doesn't trials X.X which titration, without that off that much and be to we in need weight loss be that, dose as can dose-titrated dose, straight milligram XX% XX% achieving loss population.

discussed now addition, these been So, we're that use forward. for And to primary But reduction, also dose trials a which the had in also something we allowing that give. we're other drugs. attractive employed very, we've life milligrams, X.X it other going look mimics is of employ in real and in are going for care, to going of with as dose community. and very to discussions But for that's X.X the approval

consequently, rate NAFLD and event population. the mainly discontinuation believe that shown So great we we in diabetes adverse a the have

our in by X the and out. Phase adjust finally to discontinuation are lots employing read event tirzepatide, when have in tool the which between adverse in Phase further. saw of Phase nice commonly single in believe going to semaglutide trials, We adverse their development we really X it's to X discontinuation Phase We on likewise, rates Phase XX% tools tools have improving XX% that tests dose, it for we're X program and used dissects X, our that rates became of

William Wood

couple just at coming a one you've extra, EASD. And presentations up got then of

be if or TAT. we functional give have look on showing your or and color should muscle also, to could then Maybe And data? exactly expecting, muscle far be the mass loss on what as amount us you're presenting Specifically you'll a all curious you just little muscle you VAT, in that plans patients? data, just remind expecting of me, I'm have be lean lean given least where, what do any benefit the the as you may the into muscle doses? a just we on SAT data

M. Harris

Thanks for question, William. the

details the muscle, the the that the out will on So, easel. the make TAT, VAT, presentation and plan we the in to it come SAT all

and preservation that's stay So, But design time, important. the this more incretin important. now among with preliminary there, having but information X we're agency agents, that we'll some discussion leading And meeting tuned. at benefit at Functional a that There's presentation that's the in much detailed think give mass in we Phase out September. in of right the in extremely Madrid is trial. again, lean extremely a in we're point a

tuned. on near stay to hope future. So, in We the that announce

William Wood

Congratulations again.

Operator

Our of next question JMP. comes Citizens from Jon the line from Wolleben

Jonathan Wolleben

how if mean? the body data, literature XX% seeing clinical think you're the translate Two have a anything any One, we that's you those last. on enough some a difference thoughts me. versus fat thoughts clinically. change? to what changes loss, it's or and that or the functional any on questions Do Do piggybacking composition translate And could to XX% differences on to for how meaningful

M. Harris

Thanks, Jonathan.

studies. this the was with the mass these in that is a made had a lean just that composition know about semaglutide Loss, studies label. they AHEAD actual functional loss mass Weight of pelvic And and best into not seen outcomes, effects of also XX% Look there's lean is, data the the of rate data to where So, loss change, is that mass we was body to measures in it We fractures. semaglutide asked associated fractures mass a Getting The actually poor lean there's of that X amount have that. the wealth the and on where One morbidity and SELECT that that higher about. William limited you Trial body in low bone of hip with mortality, that in trial, changes have, associated higher of talking data population trial, lean from but

is this we have. that So, the data

presenting discussion the hope as agency was extremely of new And of lean we think really with have look we're to know asked seeing that's mass are fat liver we risk. I will to substantiate at we pemvidutide. and with the cardiovascular lot be benefits. the reductions by in near we're functional I important. that a in those And that believe data of that developing of think associated prominent going But measures do that is we and future. terms also preservation meaningful have both William, here And a the we'll with that differences, visceral very and important fat

that, an in cardiovascular But recent lipids LDL studies. total profile. semaglutide, with trial, reduction the combined presented SELECT is only XX% not was serum the maybe we inflammatory We there cardio pemvidutide. X% high these with the associated That result XX% all know generally EASL lipids, but that a reduction weight improved I that So of around the at and in the minimal. as meeting the as alone. loss lipids lipoproteins, that typical the ADA reduction approximate in or getting to is in of events of cholesterol, to the With with that serum we're as compares agent Reduction effects MACE mentioned, X%. with cholesterol going

we was SELECT think a of top on do trial, the better seen outcomes conducted. we trial even the So, cardiovascular was with semaglutide in can benefit when that

Jonathan Wolleben

if that It like additional about take Can an my about, obesity might place, strategically potential a indications Pemvidutide could sense. for partnership potentially you thinking is, yourself? large, be And Phase make bit seems path a take talk forward forward too you moving mentioned are doesn't little how question program if shape, X a X pemvidutide? partnership second the doesn't but you

Vipin Garg

of our how partners First from on. meeting incretin-based interesting they're the game very partner. are asset idea try of attractive fifth up, because let a that will obesity is we very lined be think of are the outcome differentiate from we in being Jonathan, I to differentiate they're for going of Phase space. We're for also differentiated The yourself? that we're here optimistic we looking of focused at to discussions, some or focused particularly a agent to that, end continue the a it's partner that me the what players think to our see number obesity, partnership to we will on it say, In encouraging after message. name X looking trial have designs So, you're fourth getting to have and hearing but be a potential the we all, the that that's

So working on. that's exactly what we are

We're So, stay about trial for unique very bullish for obesity. X Phase our plans tuned. for pemvidutide, designed a

In addition, looking additional multiple that we have times, on we indications own. execute can at as we our mentioned are

we're that foremost, and differentiated But believe we and very attractive asset, be from it partner. that have it a will multiple So angles. to we a first approaching

Operator

Thank time, you. turn now At over Garg the closing for conference this to remarks. I Vipin would back to like

Vipin Garg

today. Thank you, our everyone, call for joining

greatly thank ongoing rest As and of your always, our support. opportunity a meaningful would wonderful for with Have you appreciate like this your we to share and day. to developments you results

Operator

Thank call. you participating. conference today's for concludes This

You disconnect. now may

Altimmune (ALT) 8 Aug 242024 Q2 Earnings call transcript